Abstract library

214 results for "chromaffin-cell tumours".
#124 Management and outcomes of malignant paragangliomas and phaeochromocytomas
Introduction: Chromaffin-cell tumors include phaeochromocytomas and paragangliomas, represent a rare group of neuroendocrine tumors and are located in adrenal medulla or extra-adrenal sites, respectively. Ten percent of phaeochromocytomas and 15-35% of paragangliomas are malignant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Christos Toumpanakis
#1103 Risk and Protective Factors for Midgut Carcinoid Tumours: A Case-Control Study of Prospectively Evaluated Patients
Introduction: The incidence of midgut carcinoid tumours is on the rise, but few studies have investigated risk factors for their occurrence.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Doctor Maria Rinzivillo
#2224 Neuroendocrine Tumours in Tailgut Cysts: A Report of 3 Cases and Review of Literature
Introduction: Retrorectal neuroendocrine tumors (NETs) are rare low grade tumors and their presence in tailgut cyst is rarer.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Prasad Pande
Authors: Pande P, D G, Shah R, Palepu J, ...
#1610 Clinical Significance of Incidental Detection of Appendicular Neuroendocrine Tumours in Sri Lanka
Introduction: Neuroendocrine tumours are known to occur in the appendix and mostly detected incidentally following appendicectomies for acute appendicitis. Most of them have a benign behavior and no clinically significant biological activity is found. However, the correct recognition of the pathology is of paramount importance as it may need a separate evaluation and management.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Dewa Pakshage Chula Kanishka Ananda Lal
Authors: Lal D P C K A, ...
Keywords: Appendicular NET
#1107 The Chicken Chorioallantoic Membrane Assay as a Preclinical Model for the Research of Rare Gastrointenstinal Neuroendocrine Tumours
Introduction: Preclinical trials of cancer therapeutics require both in vitro and in vivo evaluations. For neuroendocrine tumours (NET) studies are limited to cell lines, thus xenograft models are needed for screening and evaluation of anti-cancer drugs. The chick chorioallantoic membrane (CAM) assay is a well-established model system to investigate tumour growth, angiogenesis and metastasis.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: PhD Nassim Ghaffari Tabrizi-Wizsy
Authors: Passegger C, Kump P, Haybäck J, Lipp R, ...
#1518 Significance of Preoperative FDG-PET/CT Scan in Patients with Pulmonary Carcinoid Tumours
Introduction: FDG uptake on PET/CT scan has been shown to be of prognostic significance in patients (pts) with metastatic neuroendocrine tumours (NET).
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Georgios Papaxoinis
#1711 Survival Analysis of Combined Therapy with 177Lu-Octreotate and Somatostatin Analogues in Advanced Metastatic Neuroendocrine Tumours
Introduction: Although somatostatin analogues (SSA) and peptide receptor radionuclide therapy with 177Lu-octreotate (PRRT) are validated therapies in patients with advanced metastatic neuroendocrine tumours, it is still unclear if the combined therapy with PRRT and SSA can provide a prolonged survival compared to patients treated with PRRT alone.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr. Anna Yordanova
#1718 Enhanced Prognostication of Grade 1 Small Bowel Neuroendocrine Tumours with Multi-Parametric Clinicopathological Assessment
Introduction: Most small bowel neuroendocrine tumours (SBNET) are Grade 1 (G1), and exhibit at least nodal metastasis at diagnosis. The clinical behaviours of G1 SBNET remain poorly predictable. The ‘NET nomogram’ developed by Modlin et al. designates SBNET as low/medium/high risk by mathematical analysis of 15 clinicopathological parameters.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Ashley K Clift
Authors: Clift A K, Faiz O, Goldin R, Martin J, ...
Keywords: nomogram, stage, grade
#1777 Tumour Size Is Not a Reliable Criterion for Resection of Patients with Non-Secreting Pancreatic Neuroendocrine Tumours: Results of an International, Multi-Centre, Operative Cohort
Introduction: Small pancreatic neuroendocrine tumours (pNETs) present a management dilemma between surveillance and resection.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Logan Mills
#1850 Influence of VEGF Splicing on Microvessel Density and Architecture in Pancreatic Neuroendocrine Tumours
Introduction: Hypoxia in human tumours is associated with a poor prognosis and is characterized by the stabilization of HIF1α, upregulation of VEGF, and a high microvessel density (MVD). Interestingly, although pancreatic neuroendocrine tumours (pNETS) showing hypoxia signalling also have a poor prognosis, they paradoxically display a low MVD. We hypothesized that this paradoxon might be explained by alternative splicing of VEGF.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: MD Anja Maria Schmitt
Authors: Marinoni I, Naim S, Centeno I, Perren A, ...
Keywords: pNET, VEGF
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.